Patients call for insurance coverage of Celgene’s multiple myeloma drug

Published: 2012-07-13 06:56:00
Updated: 2012-07-13 06:56:00
Will multip myeloma patients be able to get cheaper and better drugs this year? Now all eyes are on the government’s decision on the health insurance coverage of Revlimid (lenalidomide), a new drug for multiple myeloma.

The assessment is likely to take time since Celgene, the maker of the drug...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.